|
Prospective study of UDP-glucuronosyltransferase (UGT) 2B17 genotype and exemestane (Exe) pharmacokinetics (PK) and pharmacodynamics (PD) in Asian, hormone receptor (HR) positive, metastatic breast cancer (MBC) patients. |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche |
Research Funding - Eisai (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Nesaretnam Barr Kumarakulasinghe |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Anand Devaprasath Jeyasekharan |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; Novartis |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Roche |
Research Funding - Puma Biotechnology; Zeria Pharmaceutical |
|
|
Honoraria - AstraZeneca; Eisai; Roche |
Consulting or Advisory Role - AstraZeneca; Eisai; Mundipharma; Roche |
Speakers' Bureau - Eisai; MSD; Mundipharma |
Research Funding - Amgen; MSD; Roche |
Travel, Accommodations, Expenses - Ipsen; MSD; Roche |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Bayer (Inst); Genentech (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
Research Funding - Otsuka (Inst) |
Travel, Accommodations, Expenses - Eisai; Pfizer |